Cell News and Research

RSS

Tolerx establishes Scientific Advisory Board to advance type 1 diabetes study

Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, announced today that it has established a Scientific Advisory Board to help advance the company's research and clinical studies in type 1 diabetes.

3 Nov 2010

OncoMed receives $1.2 million to support therapeutic programs under QTDP program

OncoMed Pharmaceuticals, Inc., a company developing novel therapeutics that target cancer stem cells, announced today that it has been awarded $1.2 million to support five distinct therapeutic programs under the U.S. Government's Qualifying Therapeutic Discovery Project program.

3 Nov 2010

UIC awarded $12M to study acquired and familial causes of heart failure

Researchers at the University of Illinois at Chicago have been awarded more than $12 million by the National Heart, Lung, and Blood Institute to investigate both the acquired and familial causes of heart failure -- with the aim of identifying markers for diagnosis and targets for cures.

3 Nov 2010

CTI granted additional 180 days to regain compliance with NASDAQ minimum bid price rule

Cell Therapeutics, Inc. today announced that The NASDAQ Stock Market has granted CTI an additional 180 days to regain compliance with NASDAQ's $1.00 minimum bid price rule under NASDAQ Marketplace Rule 5550(a)(2)). Previously, on May 3, 2010, CTI was notified by NASDAQ that CTI did not meet the minimum bid price rule required for continued listing and was provided until November 1, 2010 to achieve compliance.

3 Nov 2010

Immunomedics product candidates, technologies receive recognition from QTDP program

Immunomedics, Inc. a biopharmaceutical company primarily focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that all 12 applications from the Company were certified by the Internal Revenue Service of the Department of Treasury as qualified investments in accordance with the Qualifying Therapeutic Discovery Project (QTDP) program under section 48D of the Internal Revenue Code. As a result, the Company will receive an aggregate cash award of $2.9 million.

3 Nov 2010

New mouse model confirms mutation of beta-synuclein protein promotes neurodegeneration

A team of scientists from Japan and the University of California, San Diego School of Medicine have created a new mouse model that confirms that mutations of a protein called beta-synuclein promote neurodegeneration. The discovery creates a potential new target for developing treatments of diseases like Parkinson's and Alzheimer's.

3 Nov 2010

Researchers discover FoxO1 protein interacts with macrophages to promote inflammatory response

Researchers at the University of California, San Diego School of Medicine have discovered that a multi-tasking protein called FoxO1 has another important but previously unknown function: It directly interacts with macrophages, promoting an inflammatory response that can lead to insulin resistance and diabetes. Contrarily, it also generates a negative feedback loop that can limit damage from excessive inflammation.

3 Nov 2010

Avila presents results of AVL-192 preclinical studies for HCV infection at AASLD Meeting

Avila Therapeutics, Inc., a biotechnology company developing novel targeted covalent drugs, presented results today of preclinical studies that demonstrate its orally-available targeted covalent drug candidate, AVL-192, achieves superior potency against drug-resistant mutations of the Hepatitis C Virus (HCV). These new data were presented today at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) international meeting in Boston, Massachusetts.

3 Nov 2010

ImmunoGen to present clinical data of lead compounds at EORTC-NCI-AACR Symposium

ImmunoGen, Inc. a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced that several ImmunoGen poster presentations will be made at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics to be held in Berlin, Germany, November 16-19, 2010.

3 Nov 2010

CytRx receives nontaxable grant under Qualifying Therapeutic Discovery Project Program

CytRx Corporation a biopharmaceutical company specializing in oncology, today announced that it has been awarded a nontaxable grant of approximately $735,000 related to its INNO-206, tamibarotene and bafetinib programs under the Qualifying Therapeutic Discovery Project Program included in the Patient Protection and Affordable Care Act, H.R. 3590, signed into law in March 2010.

3 Nov 2010

Virus fighting just got a new boost

In a ground breaking study in the UK researchers have identified a previously unknown mechanism that allows the immune system to fight viruses even after they have infected cells. Until now it was believed that antibodies can act only before the virus enters the cells. The team now has found that antibodies that attached themselves to a virus were able to follow it into cells and help to destroy the virus before it started to reproduce. This could open up new avenues of therapy.

2 Nov 2010

Atrium completes enrollment in iCAST Atrium Registry Ultrasound Study

Atrium Medical Corporation is pleased to announce that the final patient was recently enrolled in the iCAST™ Atrium Registry Ultrasound Study (iCARUS). This study is a prospective, multi-center clinical trial studying the safety and efficacy of the Atrium iCAST™ Balloon Expandable Covered Stent in patients with occlusive disease of the iliac artery.

2 Nov 2010

Pro-Pharmaceuticals awarded $489,000 in federal grants under Qualifying Therapeutic Discovery Project

Pro-Pharmaceuticals, Inc., a developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today announced it has been notified that it has been awarded approximately $489,000 total in two federal grants under the Qualifying Therapeutic Discovery Project ("QTDP") Program.

2 Nov 2010

Type of contrast agent influences changes in stem cell proliferation

When researchers tested three different labeling agents on three different stem cell populations to determine what effect the labeling agents had on stem cell phenotype, biological behavior and migration abilities, they found changes in stem cell proliferation depending on the type of contrast agent used.

2 Nov 2010

Ligand awarded $1,955,834 federal grant under Patient Protection and Affordable Care Act

Ligand Pharmaceuticals Incorporated today announced it has been awarded $1,955,834 in immediately available funds from the U.S. government under HR: 3590 - Patient Protection and Affordable Care Act. The award comprises separate payments of approximately $245,000 for each of eight drug development programs at Ligand.

2 Nov 2010

Perrigo first quarter revenue increases 21% to record $641 million

Perrigo Company today announced results for its first quarter ended September 25, 2010.

2 Nov 2010

GSK's Revolade receives Japanese approval for treatment of chronic ITP

Ligand Pharmaceuticals Incorporated today announced its partner GlaxoSmithKline was granted approval from the Japanese Ministry of Health, Labour and Welfare for Revolade® (eltrombopag) for the treatment of the blood disorder, chronic idiopathic thrombocytopenic purpura (ITP).

2 Nov 2010

Senesco resolves NYSE Amex continued listing deficiency

Senesco Technologies, Inc. today announced that the Company has received a letter from the NYSE Amex LLC informing Senesco that it has now resolved matters related to the Company's exchange listing compliance.

2 Nov 2010

Celldex third quarter net loss increases to $9.1 million

Celldex Therapeutics, Inc. today reported financial results for the third quarter ended September 30, 2010. Celldex reported a net loss of $9.1 million, or $0.28 per share, for the third quarter of 2010 compared to a net loss of $7.2 million, or $0.45 per share, for the third quarter of 2009. For the nine months ended September 30, 2010, Celldex reported a net loss of $25.2 million, or $0.79 per share, compared to a net loss of $23.6 million, or $1.49 per share, for the nine months ended September 30, 2009.

2 Nov 2010

RegeneRx announces positive results from RGN-259 non-clinical study for Dry Eye Syndrome

RegeneRx Biopharmaceuticals, Inc. today announced the results of its first non-clinical dry eye study using RGN-259, RegeneRx's ophthalmic, preservative-free eye drop for the treatment of Dry Eye Syndrome (DES). In the study, animals were treated with RGN-259, a vehicle control and a positive control, doxycycline.

2 Nov 2010

Cell News and Research

Tolerx establishes Scientific Advisory Board to advance type 1 diabetes study

OncoMed receives $1.2 million to support therapeutic programs under QTDP program

UIC awarded $12M to study acquired and familial causes of heart failure

CTI granted additional 180 days to regain compliance with NASDAQ minimum bid price rule

Immunomedics product candidates, technologies receive recognition from QTDP program

New mouse model confirms mutation of beta-synuclein protein promotes neurodegeneration

Researchers discover FoxO1 protein interacts with macrophages to promote inflammatory response

Avila presents results of AVL-192 preclinical studies for HCV infection at AASLD Meeting

ImmunoGen to present clinical data of lead compounds at EORTC-NCI-AACR Symposium

CytRx receives nontaxable grant under Qualifying Therapeutic Discovery Project Program

Virus fighting just got a new boost

Atrium completes enrollment in iCAST Atrium Registry Ultrasound Study

Pro-Pharmaceuticals awarded $489,000 in federal grants under Qualifying Therapeutic Discovery Project

Type of contrast agent influences changes in stem cell proliferation

Ligand awarded $1,955,834 federal grant under Patient Protection and Affordable Care Act

Perrigo first quarter revenue increases 21% to record $641 million

GSK's Revolade receives Japanese approval for treatment of chronic ITP

Senesco resolves NYSE Amex continued listing deficiency

Celldex third quarter net loss increases to $9.1 million

RegeneRx announces positive results from RGN-259 non-clinical study for Dry Eye Syndrome

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest Life Science News